EarningsQ2 2026 Earnings Report
MX:GEHC Q2 2026 EPS Results
Actual EPS$20.35
Consensus EPS$18.65
Beat/MissBeat by +$1.69
One Year Ago EPS$19.09
MX:GEHC Q2 2026 Revenue Results
Actual Revenue$95.33B
Expected Revenue$94.77B
Beat/MissBeat by +$563.55M
YoY Revenue Growth+5.75%
Earnings Announcement Details
QuarterQ2 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
MX:GEHC Upcoming Earnings
GE Healthcare Technologies Inc's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:GEHC Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.Company Guidance
Record Orders, Backlog and Book-to-Bill
Organic orders growth of 11.1% (quarterly), book-to-bill of 1.15x (highest since spin), and record backlog of $23.9 billion, up $2.6 billion year-over-year and $2.1 billion sequentially.
Revenue and Service Strength
Total revenue of $5.3 billion with 3.5% organic growth. Product revenue grew 4.7% and service revenue grew 7.7%, with service benefiting from operational performance and the Intelerad acquisition.
Adjusted EPS and Profitability
Adjusted EPS of $1.13, up 6.6% year-over-year. Adjusted EBIT was $750 million and adjusted EBIT margin was 14.2% (company maintained full-year margin guidance of 15.4%–15.7%).
Pharmaceutical Diagnostics (PDx) Outperformance
PDx organic revenue grew 14.6% year-over-year with EBIT margin of 29.6%, up 30 basis points; notable strength in contrast media and U.S. radiopharmaceuticals, including double-digit growth for Vizamyl.
Advanced Imaging Solutions (AIS) Momentum
Combined AIS (recast Imaging + Advanced Visualization) organic revenue up 5% year-over-year with EBIT margin expansion of 90 basis points; company noted AIS+PDx combined growth ~6.5% with ~100 basis points margin expansion.
Flyrcado Ramp and Longer-Term PDx Opportunity
Delivered 545 Flyrcado doses for the week ending July 24 (~40% increase vs. April levels), onboarding additional customers; company remains on track toward the medium-term target of $500 million+ annual Flyrcado revenue by 2028.
New Product Pipeline and AI Initiatives
Multiple new product launches and AI-enabled software (e.g., True Definition DL and Photonova Spectra launch) showing customer traction; Photonova CE marking expected in H2 2026 to expand European opportunity.
Capital Return and Cash Guidance
Returned capital via ~$200 million of share repurchases and continued dividend. Company reiterated free cash flow guidance of approximately $1.6 billion for 2026.
MX:GEHC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed